Akebia develops and sells kidney disease medicines, including the anemia treatment Vafseo and the phosphorus control drug Auryxia. AKBA reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 8 | WestPark Capital | Initiated | Buy | |
| Aug 8 | Leerink Partners | Downgrade | Hold | |
| Jul 1 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How AKBA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in AKBA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKBA is in one of them and how their past AKBA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AKBA in an article yet. Here's the latest on the wider market.
About Akebia Therapeutics
Akebia is a biopharmaceutical company based in Waltham, Massachusetts, that develops and sells medicines for people with kidney disease. Its main product, Vafseo, is an oral treatment for anemia caused by chronic kidney disease in adults on dialysis. Its second product, Auryxia, is an oral medicine used to control phosphorus levels in dialysis patients and to treat iron deficiency anemia in adults with kidney disease who are not on dialysis. The company also develops treatments for rare kidney conditions.
- Headquarters
- Waltham, MA